Low-dose rituximab treatment in a patient with anti-neurofascin-155 IgG4 autoimmune nodopathy.
J Neuroimmunol
; 389: 578326, 2024 Apr 15.
Article
in En
| MEDLINE
| ID: mdl-38422690
ABSTRACT
Autoimmune nodopathy is a new entity of immune-mediated neuropathies associated with antibodies against nodal-paranodal epitopes. We present a detailed clinical and serological work-up of a patient with autoimmune nodopathy with anti-neurofascin-155 (anti-NF-155) IgG4 antibodies who was treated with low-dose (500 mg) rituximab, which led to a decrease of anti-NF-155 antibody titer, depletion of B cells, normalization of the levels of neurofilament light chain in serum, and significant clinical improvement. This case suggests that a low-dose rituximab could be as effective as previously reported much higher doses, and presumably with a lower risk of adverse effects and infections.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunoglobulin G
/
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Limits:
Humans
Language:
En
Journal:
J Neuroimmunol
Year:
2024
Document type:
Article